Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3014385 | 1.00 | GRIA1 (0.33) | GRIA1GRIA2GRIA3GRIA4SIRT2 | |
| SCHEMBL14287076 | 0.88 | GRIA1 (0.32) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL4373620 | 0.87 | GRIA1 (0.37) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL4373619 | 0.87 | GRIA1 (0.37) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL3025356 | 0.86 | F12 (0.33) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL3025360 | 0.86 | F12 (0.33) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL14287107 | 0.85 | PRKCA (0.36) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL14287082 | 0.85 | HIF1A (0.33) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL13592439 | 0.85 | GRIA1 (0.38) | GRIA1GRIA2GRIA3GRIA4GAA | |
| SCHEMBL13592447 | 0.85 | GRIA1 (0.38) | GRIA1GRIA2GRIA3GRIA4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | AROS PHARMA APS (DK) | 2010-08-05 | — | — | US | claimed |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | claimed |
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | AROS PHARMA APS (DK) | 2007-08-16 | — | — | US | claimed |
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | AROS PHARMA APS (DK) | 2010-08-05 | — | — | US | disclosed |
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | AROS PHARMA APS (DK) | 2010-08-05 | — | — | US | disclosed |
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | AROS PHARMA APS (DK) | 2010-08-05 | — | — | US | disclosed |
| US-7718641-B2 | Pyrrolo [3,4-H] isoquinoline compounds and methods for modulating gated ion channels | AROS PHARMA APS (DE) | 2010-05-18 | — | — | US | disclosed |
| US-7718641-B2 | Pyrrolo [3,4-H] isoquinoline compounds and methods for modulating gated ion channels | AROS PHARMA APS (DE) | 2010-05-18 | — | — | US | disclosed |
| US-7718641-B2 | Pyrrolo [3,4-H] isoquinoline compounds and methods for modulating gated ion channels | AROS PHARMA APS (DE) | 2010-05-18 | — | — | US | disclosed |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | AROS PHARMA APS (DK) | 2007-08-16 | — | — | US | disclosed |
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | AROS PHARMA APS (DK) | 2007-08-16 | — | — | US | disclosed |
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | AROS PHARMA APS (DK) | 2007-08-16 | — | — | US | disclosed |
| WO-2007059608-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | GRIA1 320/4885GRIA2 244/4885GRIA3 182/4885 |
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | KCNQ1, KCNQ2, KCNH3 | GRIA1 241/4885GRIA2 186/4885GRIA3 141/4885 |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | ASIC1, ASIC3, TRPV1 | GRIA1 347/4885GRIA2 247/4885GRIA3 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.